LIFEVANTAGE CORP Deferred Tax Liabilities, Gross
LIFEVANTAGE CORP (LFVN) had Deferred Tax Liabilities, Gross of $2.78 million as of 2026-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-08-27
- 2026-06-30: Deferred Tax Liabilities, Gross $2.78M.
- 2025-06-30: Deferred Tax Liabilities, Gross $2.67M.
- 2024-06-30: Deferred Tax Liabilities, Gross $3.56M.
- 2023-06-30: Deferred Tax Liabilities, Gross $4.16M.
| Period end | Deferred Tax Liabilities, Gross | Deferred Tax Liabilities, Gross as first filed |
|---|---|---|
| 2026-06-30 | $2.78M 10-K · filed 2026-08-27 | |
| 2025-06-30 | $2.67M 10-K · filed 2026-08-27 | |
| 2024-06-30 | $3.56M 10-K · filed 2025-09-04 | |
| 2023-06-30 | $4.16M 10-K · filed 2024-08-28 | |
| 2022-06-30 | $4.73M 10-K · filed 2023-08-28 | $2.48M 10-K · filed 2022-08-23 |
| 2021-06-30 | $1.54M 10-K · filed 2022-08-23 | |
| 2020-06-30 | $977.00K 10-K · filed 2021-08-19 | |
| 2019-06-30 | $1.43M 10-K · filed 2020-08-18 | |
| 2018-06-30 | $981.00K 10-K · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |